CUI1 stringlengths 8 8 | RELA stringlengths 3 54 | CUI2 stringlengths 8 8 | Name1 stringlengths 1 2.86k ⌀ | Name2 stringlengths 1 2.86k ⌀ | Def1 stringlengths 1 8.95k ⌀ | Def2 stringlengths 1 8.95k ⌀ |
|---|---|---|---|---|---|---|
C0000294 | may_be_treated_by | C0019080 | mesna | Hemorrhage | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | Bleeding or escape of blood from a vessel. |
C0000294 | has_ingredient | C0987640 | mesna | mesna 100 MG/ML | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C1125277 | mesna | mesna 50 MG/ML | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C1126451 | mesna | mesna 16.67 MG/ML | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C1130658 | mesna | mesna 400 MG | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C1130659 | mesna | mesna 600 MG | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_part | C1170010 | mesna | ifosfamide / mesna | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C1246850 | mesna | mesna Oral Tablet | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C1248609 | mesna | mesna Injectable Solution | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C1251469 | mesna | ifosfamide / mesna Injectable Solution | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | physiologic_effect_of | C1372554 | mesna | Increased Renal Organic Ion Excretion | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mechanism_of_action_of | C2266866 | mesna | Binding Activity | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C3210723 | mesna | ifosfamide / mesna Injectable Product | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C3215349 | mesna | mesna Injectable Product | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C3215351 | mesna | mesna Oral Product | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C3215352 | mesna | mesna Pill | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | therapeutic_class_of | C4722030 | mesna | Genitourinary Agents [TC] | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C0678115 | mesna | Uromitexan | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C0721681 | mesna | Mesnex | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C0733874 | mesna | Mistabron | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C0733875 | mesna | Mitexan | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | lab_number_of | C0733876 | mesna | UCB-3983 | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C1513147 | mesna | Ausobronc | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C1513148 | mesna | Filesna | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C1513149 | mesna | Mesnil | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C1513150 | mesna | Mexan | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C1513153 | mesna | Mucolene | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C1513154 | mesna | Ziken | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | lab_number_of | C1521833 | mesna | D-7093 | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C5441835 | mesna | Mucofluid | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_component | C0338297 | mesna | Etoposide/Ifosfamide/Mesna/Mitoxantrone | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_component | C0338361 | mesna | dacarbazine/doxorubicin/ifosfamide/mesna protocol | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_component | C0393025 | mesna | Carmustine/Cyclophosphamide/Etoposide/Mesna | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_component | C0393040 | mesna | cisplatin/ifosfamide/mesna/mitomycin protocol | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_component | C0393047 | mesna | Etoposide/Ifosfamide/Mesna Regimen | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | A regimen consisting of etoposide, ifosfamide and mesna that may be used in the treatment of breast cancer, bone cancer, and recurrent sarcomas. |
C0000294 | has_component | C0393048 | mesna | Ifosfamide/Mesna/Mitoxantrone | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_component | C0393055 | mesna | Carboplatin/Ifosfamide/Mesna | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_component | C0393056 | mesna | Carboplatin/filgrastim/Ifosfamide/Mesna | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_component | C0677749 | mesna | Etoposide/Ifosfamide/Mesna/Topotecan | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C0678115 | mesna | Uromitexan | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C0721681 | mesna | Mesnex | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C0733874 | mesna | Mistabron | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C0733875 | mesna | Mitexan | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C1513147 | mesna | Ausobronc | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C1513148 | mesna | Filesna | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C1513149 | mesna | Mesnil | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C1513150 | mesna | Mexan | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C1513153 | mesna | Mucolene | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C1513154 | mesna | Ziken | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C5441835 | mesna | Mucofluid | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | inverse_isa | C1519837 | mesna | Uroprotective Agent | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | Agents administered before, with, or after cancer therapy to reduce or prevent damage or toxicity to the urinary tract. (NCI) |
C0000294 | chemotherapy_regimen_has_component | C0065541 | mesna | MAID protocol | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | A regimen consisting of doxorubicin, ifosfamide, dacarbazine and mesna used to treat unresectable soft tissue sarcoma. |
C0000294 | chemotherapy_regimen_has_component | C0338297 | mesna | Etoposide/Ifosfamide/Mesna/Mitoxantrone | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | chemotherapy_regimen_has_component | C0338361 | mesna | dacarbazine/doxorubicin/ifosfamide/mesna protocol | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | chemotherapy_regimen_has_component | C0386586 | mesna | MINE regimen | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | A regimen consisting of mesna, ifosfamide, mitoxantrone and etoposide that can be used to treat acute lymphoblastic leukemia (ALL), Hodgkin and Non-Hodgkin lymphoma, including diffuse large B-cell lymphoma. |
C0000294 | chemotherapy_regimen_has_component | C0393025 | mesna | Carmustine/Cyclophosphamide/Etoposide/Mesna | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | chemotherapy_regimen_has_component | C0393040 | mesna | cisplatin/ifosfamide/mesna/mitomycin protocol | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | chemotherapy_regimen_has_component | C0393047 | mesna | Etoposide/Ifosfamide/Mesna Regimen | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | A regimen consisting of etoposide, ifosfamide and mesna that may be used in the treatment of breast cancer, bone cancer, and recurrent sarcomas. |
C0000294 | chemotherapy_regimen_has_component | C0393048 | mesna | Ifosfamide/Mesna/Mitoxantrone | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | chemotherapy_regimen_has_component | C0393055 | mesna | Carboplatin/Ifosfamide/Mesna | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | chemotherapy_regimen_has_component | C0393056 | mesna | Carboplatin/filgrastim/Ifosfamide/Mesna | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | chemotherapy_regimen_has_component | C0673828 | mesna | TIP regimen | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | A regimen consisting of paclitaxel, ifosfamide, mesna and cisplatin that may be used for the treatment of non-urothelial and urothelial bladder cancer, gestational trophoblastic neoplasia (GTN), malignant germ cell tumors, penile cancer, testicular cancer, and squamous cell head and neck cancer. |
C0000294 | chemotherapy_regimen_has_component | C0677749 | mesna | Etoposide/Ifosfamide/Mesna/Topotecan | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_gdc_value | C1254351 | mesna | Pharmacologic Substance | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances. |
C0000294 | chemotherapy_regimen_has_component | C1511713 | mesna | Dacarbazine/Mesna | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | A combination of agents containing dacarbazine and mesna. |
C0000294 | chemotherapy_regimen_has_component | C1879509 | mesna | AIM Regimen | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | A regimen consisting of doxorubicin, ifosfamide and mesna that can be used for the treatment of unresectable soft tissue sarcoma and uterine sarcoma. |
C0000294 | chemotherapy_regimen_has_component | C1879911 | mesna | CALGB 9251 Regimen | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | A regimen comprised of a prephase (or cytoreductive phase), followed by two different chemotherapy regimens, given on an alternating schedule and used to treat adult L3 acute lymphoblastic leukemia (ALL3 or Burkitt's-type) and adult small non-cleaved cell (Burkitt's) lymphoma. |
C0000294 | chemotherapy_regimen_has_component | C1879969 | mesna | CODOX-M Alternating with IVAC Regimen | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | A regimen that alternates cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate (CODOX-M) with ifosfamide, etoposide and high-dose cytarabine (IVAC), and can be used in the treatment of Burkitt lymphoma and Burkitt-like lymphoma. |
C0000294 | subset_includes_concept | C1880653 | mesna | FDA Established Names and Unique Ingredient Identifier Codes Terminology | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | The terminology that includes terms pertaining to FDA/USP Substance Registration System (SRS), which is to support health information technology initiatives by generating unique ingredient identifiers (UNIIs) for substances in drugs, biologics, foods, and devices. |
C0000294 | chemotherapy_regimen_has_component | C1882524 | mesna | R-ICE Regimen | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | A chemoimmunotherapy regimen consisting of rituximab, ifosfamide, carboplatin and etoposide used to treat indolent and aggressive forms of non-Hodgkin lymphoma; also used to treat relapsed and refractory non-Hodgkin lymphoma. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63465" NCI Thesaurus) |
C0000294 | subset_includes_concept | C3899741 | mesna | CTRP Terminology | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | Terminology that is used to support NCI's Clinical Trials Reporting Program (CTRP), a database that captures the required reporting data for all NCI-sponsored clinical trials. |
C0000294 | subset_includes_concept | C3899744 | mesna | CTRP Agent Terminology | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | A subset of terminology about pharmacologic substances and formulations that are currently being used or tested in clinical trials for the treatment of cancer, cancer-related conditions and chemo/radiotherapy-related side effects. |
C0000294 | subset_includes_concept | C4763808 | mesna | GDC Terminology | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | Terminology that supports the Genomic Data Commons (GDC). |
C0000294 | subset_includes_concept | C4763809 | mesna | GDC Therapeutic Agent Terminology | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | chemotherapy_regimen_has_component | C5202856 | mesna | CIM Regimen | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | A regimen consisting of cisplatin, ifosfamide, and mesna that may be used in the treatment of endometrial and ovarian cancer, and malignant mixed Müllerian tumors. |
C0000294 | chemotherapy_regimen_has_component | C5205309 | mesna | Ifosfamide/Paclitaxel Regimen | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | A regimen consisting of ifosfamide, mesna and paclitaxel that can be used in the treatment of uterine, ovarian, fallopian tube, or primary peritoneal cancer, malignant germ cell tumors, malignant sex cord-stromal tumors, and certain carcinosarcomas, such as malignant mixed Müllerian tumors. |
C0000294 | chemotherapy_regimen_has_component | C5206220 | mesna | Fluorouracil/Ifosfamide/Mesna/Methotrexate Regimen | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | A regimen consisting of ifosfamide, mesna, methotrexate and 5-fluorouracil that may be used in the treatment of breast cancer. |
C0000294 | chemotherapy_regimen_has_component | C5207000 | mesna | MINE-ESHAP Regimen | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | A regimen consisting of mesna, ifosfamide, mitoxantrone and etoposide (MINE) alternated with etoposide, methylprednisolone, high-dose cytarabine, and cisplatin (ESHAP) that may be used in the treatment of Hodgkin and non-Hodgkin lymphomas. |
C0000294 | subset_includes_concept | C5447243 | mesna | NCI Drug Dictionary Terminology | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | Terminology created to support the National Cancer Institute (NCI) Drug Dictionary. |
C0000294 | subset_includes_concept | C5447840 | mesna | GDC Value Terminology | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | Terminology that supports the values for properties in the Genomic Data Commons (GDC) data model. |
C0000294 | chemotherapy_regimen_has_component | C5891085 | mesna | Etoposide/Ifosfamide/Mesna/Mitoxantrone/Rituximab Regimen | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | A regimen consisting of etoposide, ifosfamide, mesna, mitoxantrone and rituximab that may be used in the treatment of diffuse large B-cell lymphoma (DLBCL). |
C0000294 | subset_includes_concept | C5910040 | mesna | HemOnc Agent Terminology | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | A terminology set that includes pharmacologic agents found in the HemOnc knowledge base. |
C0000294 | has_ingredient | C0543371 | mesna | mesna 400 MG Oral Tablet | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C0704829 | mesna | mesna 100 MG/ML Injectable Solution | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C0977727 | mesna | IFOSFAMIDE 1GM/VIL/MESNA 200MG/AMP PKG INJ | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C0977728 | mesna | {2 (60 ML ifosfamide 50 MG/ML Injection) / 6 (mesna 100 MG/ML Injectable Solution) } Pack | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C0977729 | mesna | IFOSFAMIDE 3GM/VIL/MESNA 400MG/AMP PKG INJ | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C3495651 | mesna | (Ifosfamide 50 MG/ML Injectable Solution) / (Mesna 100 MG/ML Injectable Solution) Pack Includes 10/10 & 5/3 Kit | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000300 | inverse_isa | C0007090 | 2-Naphthylamine | Carcinogens | A naphthalene derivative with carcinogenic action. | Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. |
C0000300 | mapped_to | C0045354 | 2-Naphthylamine | 2,3-diaminonaphthalene | A naphthalene derivative with carcinogenic action. | null |
C0000300 | mapped_to | C0047561 | 2-Naphthylamine | 3-methyl-2-naphthylamine | A naphthalene derivative with carcinogenic action. | null |
C0000300 | mapped_to | C0048448 | 2-Naphthylamine | 4-methoxy-2-naphthylamine | A naphthalene derivative with carcinogenic action. | null |
C0000300 | mapped_to | C0050105 | 2-Naphthylamine | 8-methoxy-2-(N-2'-chloropropyl-N-propyl)aminotetralin | A naphthalene derivative with carcinogenic action. | null |
C0000300 | mapped_to | C0050592 | 2-Naphthylamine | acrylodan | A naphthalene derivative with carcinogenic action. | null |
C0000300 | mapped_to | C0053837 | 2-Naphthylamine | black rubber | A naphthalene derivative with carcinogenic action. | null |
C0000300 | mapped_to | C0067499 | 2-Naphthylamine | 2-piperazinotetralin | A naphthalene derivative with carcinogenic action. | null |
C0000300 | mapped_to | C0068023 | 2-Naphthylamine | N-hydroxy-2-naphthylamine | A naphthalene derivative with carcinogenic action. | null |
C0000300 | mapped_to | C0068546 | 2-Naphthylamine | neozone | A naphthalene derivative with carcinogenic action. | null |
C0000300 | mapped_to | C0072064 | 2-Naphthylamine | prodan | A naphthalene derivative with carcinogenic action. | null |
C0000300 | mapped_to | C0083196 | 2-Naphthylamine | laurdan | A naphthalene derivative with carcinogenic action. | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.